Molina Healthcare vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Long Beach CA Medicaid managed care (NYSE: MOH) ~$38.7B FY2024 revenue; 5.7M members in 19 states, Medicaid redetermination management, D-SNP growth competing with Centene and Elevance.
About
Molina Healthcare, Inc. is a Long Beach, California-based managed care organization — publicly traded on the New York Stock Exchange (NYSE: MOH) as an S&P 500 Health Care component — providing Medicaid, Medicare, and Marketplace (Affordable Care Act exchange) health insurance through state-contracted managed care plans to approximately 5.7 million low-income, elderly, and disabled members across 19 states, with revenues generated primarily from per-member-per-month (PMPM) capitation payments received from state Medicaid agencies and CMS Medicare programs. In fiscal year 2024, Molina Healthcare reported revenues of approximately $38.7 billion — primarily from Medicaid capitation payments from state Medicaid agencies that contract with Molina to administer benefits for enrolled beneficiaries — generating net income impacted by elevated medical costs in the Marketplace segment as post-COVID health utilization normalization drove medical loss ratios above expectations. CEO Joseph Zubretsky's strategy of disciplined Medicaid contract renewal and Medicaid redetermination management positioned Molina for the 2023-2024 Medicaid unwinding — the federal pandemic-era continuous enrollment requirement expiration required states to redetermine eligibility for all Medicaid enrollees, with Molina proactively assisting ineligible members transition to Marketplace plans to retain the relationship. Molina's marketplace business expansion (Affordable Care Act exchange plans in new states and existing markets) provides enrollment growth offsetting Medicaid membership losses from redetermination, while Medicare Dual Eligible Special Needs Plans (D-SNPs — serving members eligible for both Medicaid and Medicare) represent the highest-growth and highest-margin Molina product line.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Molina Healthcare vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.